Danish drug maker Novo Nordisk posts 2Q profit rise, helped by insulin sales

Denmark’s Novo Nordisk posts rise in 2Q profits

COPENHAGEN — Danish drug maker Novo Nordisk A/S on Thursday said second-quarter net profit rose by 21 percent, aided by a surge in insulin sales in North America.

Full article »

Moody’s improves outlook for Bristol-Myers Squibb following FDA approval for Onglyza

Moody’s lifts Bristol-Myers outlook to ‘Stable’

NEW YORK — Moody’s Investors Service raised its outlook on drugmaker Bristol-Myers Squibb Co. to “Stable” from “Negative” Monday after regulators approved Bristol-Myers’ diabetes treatment Onglyza.

Full article »

FDA clears potential blockbuster diabetes drug from drugmakers Bristol-Myers and AstraZeneca

FDA approves new diabetes drug Onglyza

WASHINGTON — Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.

Full article »

Sanofi-Aventis 2Q net profit up 4.9 percent on higher sales of key drugs

Sanofi-Aventis 2Q profit up 4.9 percent

PARIS — Pharmaceutical company Sanofi-Aventis said Wednesday its net profit rose 4.9 percent in the second quarter on stronger sales of its diabetes drug Lantus and blood thinners Lovenox and Plavix.

Full article »

Sanofi-Aventis Q2 net profit up 5 percent on higher sales of key drugs

Sanofi-Aventis Q2 profit up 5 percent

PARIS — Pharmaceutical company Sanofi-Aventis reported Wednesday a 5 percent increase in second-quarter net profit, due to stronger sales of its diabetes drug Lantus and blood thinners Lovenox and Plavix, which it predicted would boost full-year earnings.

Full article »

Drugmaker Sanofi-Aventis to close some research labs, review status of others in restructuring

Sanofi-Aventis to close some plants, restructure

PARIS — French drugmaker Sanofi-Aventis SA announces a major corporate restructuring on the heels of new safety concerns that could hurt sales of a key drug, its once-a-day insulin Lantus.

Full article »

FDA panel says AstraZeneca, Pfizer, Lilly drugs appear safe for adolescents, children

FDA panel backs 3 psychiatric drugs for kids

ADELPHI, Md. — Advisers to the Food and Drug Administration said Wednesday that three blockbuster psychiatric drugs appear safe and effective for children and adolescents, despite side effects that can increase the risk of diabetes.

Full article »

FDA advisers to vote on potential approval of 3 more anti-psychotic drugs for youngsters

FDA panel to vote on psychiatric drugs for kids

WASHINGTON — Advisers to the Food and Drug Administration are scheduled to vote Wednesday on whether three powerful psychiatric drugs should be approved for children, despite side effects that can increase the risk of diabetes.

Full article »


Protected by Comment Guard Pro